Jan 17, 2022

The increase in obese population and rise in prevelance of cancer to drive the growth of Antibody Drug Conjugates (ADCs) – Linker and Conjugation Tech

Antibody Drug conjugates (ADCs) are innovative anticancer drugs that deliver chemotherapy agents to cancer cells by attaching them to monoclonal antibodies via stable linkers. After binding to the target, the ADC releases a cytotoxic drug into the cancer cell. The linkers play an essential role as their properties strongly influence the ADC's therapeutic index, pharmacokinetics, and efficacy. Advances in linker technology are needed to significantly improve the delivery of a cytotoxic agent to cancer cells.

Increased prevalence of cancer across the globe, growing aging population, increasing R&D activities for cancer drug therapies, advancements in linker technology, rising government investments for cancer research are the factors expected to catalyze the development of this market over the forecast period. The increasing mergers and collaborations between drug developers and technology providers to improve ADC candidates and other conjugated pharmaceuticals are projected to offer significant market growth opportunities in the next few years. However, high capital investments, complex manufacturing processes, and the lack of reimbursement policies may hamper market adoption in the upcoming years.

Companies Mentioned:

  • Seattle Genetics, Inc.
  • ImmunoGen
  • Ambrx
  • Catalent Biologics
  • Immunomedics
  • Mersana Therapeutics
  • Sutro Biopharma
  • Iksuda Therapeutics
  • LegoChem Biosciences
  • LinXis
  • ADC therapeutics
  • NBE Therapeutics
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • AbbVie Inc
  • AstraZeneca plc
  • Oxford BioTherapeutics Ltd.
  • Novartis AG
  • Angiex
  • Levena Biopharma
  • Synthon
  • Bayer Healthcare Pharmaceuticals
  • Zymeworks
  • Spirogen
  • Cerbios-Pharma
  • Other Prominent Players

 

Market Segments

Global Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies Market, based on ADC Linker Technologies Type, 2019-2030 (Value US$ Mn)

  • Non-cleavable Linkers
  • Cleavable Linkers

Global Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies Market, based on ADC Conjugation Technologies Type, 2019-2030 (Value US$ Mn)

  • Chemical Conjugation
  • Enzymatic Conjugation

Global Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies Market, based on Application, 2019-2030 (Value US$ Mn)

  • Leukemia
  • Lymphoma
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor

Global Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies Market, based on Region, 2019-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies Market, by Country, 2019-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies Market, by Country, 2019-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies Market, by Country, 2019-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies Market, by Country, 2019-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies Market, by Country, 2019-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Why should buy this report:

  • To receive a comprehensive analysis of the prospects for the global Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies market
  • To receive an industry overview and future trends of the Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies market
  • To analyze the Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies market drivers and challenges
  • To get information on the Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies market size (Value US$ Mn) forecast to 2030
  • Significant investments, mergers & acquisitions in the Antibody Drug Conjugates (ADCs) – Linker And Conjugation Technologies market industry